Korean Journal of Food Science and Technology (한국식품과학회지)

Korean Society of Food Science and Technology (한국식품과학회)
권호 표지
DOI QR코드

DOI QR Code

Flavonoids baicalein and kaempferol reduced inflammation in benign prostate hyperplasia patient-derived cells through regulating mitochondrial respiration and intracellular oxygen species

  • Lee, Dongu (Department of Urology, College of Medicine, Yonsei University) ;
  • Lee, Jong Hun (Department of Food Science and Biotechnology, Gachon University) ;
  • Lee, Seung Hwan (Department of Urology, College of Medicine, Yonsei University)
  • Received : 2021.03.13
  • Accepted : 2021.04.12
  • Published : 2021.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Benign prostate hyperplasia (BPH) is one of the most common elderly disease, and because of prolonged incubation period and many side effects of medication or surgical interventions, the use of dietary phytochemicals is considered as an effective measure for prevention of BPH. The purpose of this study is to investigate the mechanism of inhibition effect for BPH by flavonoids such as baicalein and kaempferol. BPH cells were collected through biopsy from patients with PSA of 4 or higher, followed by primary culture. In vitro experiments were conducted to evaluate mitochondrial respiration, intracellular reactive oxygen species (ROS) level and expression of inflammatory markers, genes, and anti-oxidants. In conclusion, baicalein and kaempferol have been demonstrated to inhibit BPH through lowering ROS, thereby reducing inflammation triggers, and reduced inflammation. This study is expected to be helpful in the development of flavonoids that have a clinical effect on suppressing BPH.

Keywords

References

  1. Abdel-Aziz AM, Gamal El-Tahawy NF, Salah Abdel Haleem MA, Mohammed MM, Ali AI, Ibrahim YF. Amelioration of testosterone-induced benign prostatic hyperplasia using febuxostat in rats: The role of VEGF/TGFbeta and iNOS/COX-2. Eur. J. Pharmacol. 889: 173631 (2020) https://doi.org/10.1016/j.ejphar.2020.173631
  2. Ahmad M, Suhail N, Mansoor T, Banu N, Ahmad S. Evaluation of oxidative stress and DNA damage in benign prostatic hyperplasia patients and comparison with controls. Indian J. Clin. Biochem. 27: 385-388 (2012) https://doi.org/10.1007/s12291-012-0229-4
  3. Aydin A, Arsova-Sarafinovska Z, Sayal A, Eken A, Erdem O, Erten K, Ozgok Y, Dimovski A. Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostatic hyperplasia. Clin. Biochem. 39: 176-179 (2006) https://doi.org/10.1016/j.clinbiochem.2005.11.018
  4. Bosch JL, Hop WC, Kirkels WJ, Schroder FH. Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. Urology 46: 34-40 (1995) https://doi.org/10.1016/S0090-4295(99)80248-9
  5. Bostanci Y, Kazzazi A, Momtahen S, Laze J, Djavan B. Correlation between benign prostatic hyperplasia and inflammation. Curr. Opin. Urol. 23: 5-10 (2013) https://doi.org/10.1097/MOU.0b013e32835abd4a
  6. De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schroder F, Sciarra A, Tubaro A. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur. Urol. 60: 106-117 (2011) https://doi.org/10.1016/j.eururo.2011.03.055
  7. Dedhia RC, McVary KT. Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J. Urol. 179: 2119-2125 (2008) https://doi.org/10.1016/j.juro.2008.01.094
  8. Devi KP, Malar DS, Nabavi SF, Sureda A, Xiao J, Nabavi SM, Daglia M. Kaempferol and inflammation: From chemistry to medicine. Pharmacol. Res. 99: 1-10 (2015) https://doi.org/10.1016/j.phrs.2015.05.002
  9. Fourcade RO, Theret N, Taieb C, Group BUS. Profile and management of patients treated for the first time for lower urinary tract symptoms/benign prostatic hyperplasia in four European countries. BJU Int. 101: 1111-1118 (2008) https://doi.org/10.1111/j.1464-410X.2008.07498.x
  10. Goldmann WH, Sharma AL, Currier SJ, Johnston PD, Rana A, Sharma CP. Saw palmetto berry extract inhibits cell growth and Cox-2 expression in prostatic cancer cells. Cell Biol. Int. 25: 1117-1124 (2001) https://doi.org/10.1006/cbir.2001.0779
  11. Isaacs JT. Etiology of benign prostatic hyperplasia. Eur. Urol. 25 Suppl 1: 6-9 (1994) https://doi.org/10.1159/000475324
  12. Kansanen E, Kuosmanen SM, Leinonen H, Levonen AL. The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer. Redox Biol. 1: 45-49 (2013) https://doi.org/10.1016/j.redox.2012.10.001
  13. Keehn A, Lowe FC. Complementary and alternative medications for benign prostatic hyperplasia. Can. J. Urol. 22 Suppl 1: 18-23 (2015)
  14. Kirby RS. The natural history of benign prostatic hyperplasia: what have we learned in the last decade? Urology 56: 3-6 (2000) https://doi.org/10.1016/S0090-4295(00)00747-0
  15. Kullisaar T, Turk S, Punab M, Mandar R. Oxidative stress-cause or consequence of male genital tract disorders? Prostate 72: 977-983 (2012) https://doi.org/10.1002/pros.21502
  16. Lee JH, Khor TO, Shu L, Su Z-Y, Fuentes F, Kong A-NT. Dietary phytochemicals and cancer prevention: Nrf2 signaling, epigenetics, and cell death mechanisms in blocking cancer initiation and progression. Pharmacol. Ther. 137: 153-171 (2013) https://doi.org/10.1016/j.pharmthera.2012.09.008
  17. Lee W, Ku SK, Bae JS. Anti-inflammatory effects of Baicalin, Baicalein, and Wogonin in vitro and in vivo. Inflammation 38: 110-125 (2015) https://doi.org/10.1007/s10753-014-0013-0
  18. Lee S, Lee H, Kim KT. Optimization of experimental conditions and measurement of oxygen consumption rate (OCR) in zebrafish embryos exposed to organophosphate flame retardants (OPFRs). Ecotoxicol. Environ. Saf. 182: 109377 (2019) https://doi.org/10.1016/j.ecoenv.2019.109377
  19. Mahmood T, Yang PC. Western blot: technique, theory, and trouble shooting. N. Am. J. Med. Sci. 4: 429-434 (2012) https://doi.org/10.4103/1947-2714.100998
  20. Sciarra A, Mariotti G, Salciccia S, Autran Gomez A, Monti S, Toscano V, Di Silverio F. Prostate growth and inflammation. J. Steroid Biochem. Mol. Biol. 108: 254-260 (2008) https://doi.org/10.1016/j.jsbmb.2007.09.013
  21. TeSlaa T, Teitell MA. Techniques to monitor glycolysis. Methods Enzymol. 542: 91-114 (2014) https://doi.org/10.1016/B978-0-12-416618-9.00005-4
  22. Zhang J, Zhang Q. Using Seahorse machine to measure OCR and ECAR in cancer cells. Methods Mol. Biol. 1928: 353-363 (2019) https://doi.org/10.1007/978-1-4939-9027-6_18